GI
CYTK icon

GAMMA Investing’s Cytokinetics CYTK Stock Holding History

GAMMA Investing’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$178K Buy
2,700
+213
+9% +$16.2K 0.01% 1427
2026
Q2 		$212K Buy
2,487
+266
+12% +$19.1K 0.01% 1231
2026
Q1 		$146K Buy
2,221
+165
+8% +$10.5K 0.01% 1354
2025
Q4 		$131K Buy
2,056
+584
+40% +$36.3K 0.01% 1376
2025
Q3 		$80.9K Buy
1,472
+769
+109% +$31.7K ﹤0.01% 1660
2025
Q2 		$23.2K Sell
703
-417
-37% -$14.5K ﹤0.01% 2379
2025
Q1 		$45K Buy
1,120
+826
+281% +$38K ﹤0.01% 1864
2024
Q4 		$13.8K Sell
294
-305
-51% -$15.8K ﹤0.01% 2454
2024
Q3 		$31.6K Buy
599
+141
+31% +$7.86K ﹤0.01% 1814
2024
Q2 		$24.8K Sell
458
-158
-26% -$9.54K ﹤0.01% 1703
2024
Q1 		$43.2K Sell
616
-402
-39% -$31.1K 0.01% 1133
2023
Q4 		$79.5K Buy
+1,018
New +$36.9K 0.02% 643

Other funds holding CYTK

MCP
Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return
VC
Veracity Capital Atlanta, Georgia $372M AUM 32.95% 1-Year Est. Return
BCG
Breakwater Capital Group Paramus, New Jersey $844M AUM 15.36% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
EWP
Elevation Wealth Partners Santa Rosa, California $356M AUM 17.04% 1-Year Est. Return
TC
Trust Company Manhattan, Kansas $1.15B AUM 7.83% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return

GAMMA Investing's CYTK Position: Q3 2026 in Review

GAMMA Investing increased its Cytokinetics (CYTK) stake by 8.6% in Q3 2026, buying an estimated $16.2K and bringing the position to 2,700 shares worth $178K. The position accounts for 0.01% of the portfolio, ranked #1427.

GAMMA Investing first reported a position in CYTK in Q4 2023 and has held it in 12 quarters since. The position peaked at $212K in Q2 2026. 10 funds tracked by Wall St. Rank hold CYTK as of Q3 2026.

  • GAMMA Investing held 2,700 shares of Cytokinetics worth $178K as of Q3 2026.
  • GAMMA Investing bought 213 Cytokinetics shares in Q3 2026, an estimated $16.2K.
  • Cytokinetics made up 0.01% of GAMMA Investing's portfolio in Q3 2026, its #1427 holding.
  • GAMMA Investing first reported a position in Cytokinetics in Q4 2023 and has held it in 12 quarters since.
  • GAMMA Investing's Cytokinetics position peaked at $212K in Q2 2026.
  • 10 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.